OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers (VSEs™).

Breakthrough technology is both intimidating and exhilarating

To achieve the promise of viral medicine, though, the innovation of many is needed. We’re here to guide the way. Let our scientific experience and expertise support you, your science and your business. Let’s talk.

Have a question? Contact Virica